Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Warfarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 known ✓ | Q9BQB6 | 3/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.90 |
| ▸ | ALB | P02768 | 2/20 | 0.90 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.90 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.90 |
| ▸ | MEN1 | O00255 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | BRD4 | O60885 | 1/20 | 0.63 |
| ▸ | NQO1 | P15559 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Warfarin SCHEMBL5013797 | 0.96 | CYP2C9 (0.88) | CYP2C9VKORC1ALBHSD17B10ALDH1A1 | |
| Warfarin SCHEMBL3689 | 0.95 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10ALDH1A1 | |
| Warfarin SCHEMBL662875 | 0.95 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10ALDH1A1 | |
| Warfarin SCHEMBL2139452 | 0.95 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10ALDH1A1 | |
| Warfarin SCHEMBL4439794 | 0.95 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10ALDH1A1 | |
| Warfarin SCHEMBL3792087 | 0.95 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10ALDH1A1 | |
| Warfarin SCHEMBL29400364 | 0.95 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10ALDH1A1 | |
| Warfarin SCHEMBL13278154 | 0.94 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10ALDH1A1 | |
| Warfarin SCHEMBL34347 | 0.94 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10ALDH1A1 | |
| Warfarin SCHEMBL8332637 | 0.94 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845285-B2 | Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto | CYMABAY THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160280636-A1 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto | DIATEX, INC. | 2016-09-29 | — | — | US | disclosed |
| US-9233914-B2 | Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto | CYMABAY THERAPEUTICS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150225333-A1 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto | DIATEX, INC. | 2015-08-13 | — | — | US | disclosed |
| US-8993797-B2 | Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto | CYMABAY THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140024852-A1 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto | DIATEX, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8507719-B2 | Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto | METABOLEX, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8481597-B2 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia | METABOLEX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8354448-B2 | Use of (−)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of type 2 diabetes | METABOLEX, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8329749-B2 | Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia | METABOLEX, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20030220399-A1 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia | METABOLEX, INC. | 2003-11-27 | — | — | US | disclosed |
| US-6646004-B1 | Administering antidiabetic agents such as 2-acetamidoethyl-4-chlorophenyl-(3-trifluoromethylphenoxy)acetate, having side effect reduction | METABOLEX, INC. | 2003-11-11 | — | — | US | disclosed |
| US-6624194-B1 | 3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. Provides (3-trihalomethylphenoxy) (4-halophenyl) acetic acid for | METABOLEX, INC. | 2003-09-23 | — | — | US | disclosed |
| EP-1343493-A2 | USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA | METABOLEX, INC. (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6613802-B1 | Composition containing (-) enantiomer of compound in enantiomeric excess of at least 80% relative to (+) enantiomer, which exhibits reduced inhibition of cytochrome P450 2C9 | METABOLEX, INC. | 2003-09-02 | — | — | US | disclosed |
| WO-2002044113-A9 | USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA | METABOLEX INC (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2002044113-A2 | USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA | METABOLEX, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-1183020-A2 | USE OF(-)(3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL)ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6262118-B1 | THERAPY OF TYPE 2 DIABETES IN A MAMMAL BY ADMINISTERING (-) 4-CHLOROPHENYL-(3-TRIFLUOROMETHYLPHENOXY)ACETIC ACID DERIVATIVE | METABOLEX, INC. | 2001-07-17 | — | — | US | disclosed |
| WO-2000074666-A2 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280636-A1 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto | LIPA, SLC5A2, SLC2A2 | VKORC1 3327/4885CYP2C9 2640/4885ALB 67/4885 |
| US-20150225333-A1 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto | LIPA, SLC5A2, SLC2A2 | VKORC1 3327/4885CYP2C9 2640/4885ALB 67/4885 |
| US-20140024852-A1 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto | LIPA, SLC5A2, SLC2A2 | VKORC1 3327/4885CYP2C9 2640/4885ALB 67/4885 |
| US-20030220399-A1 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia | HACL2, SLC5A2, HCAR2 | VKORC1 3465/4885CYP2C9 1458/4885ALB 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.